Evoke Pharma, Inc.
EVOK
$10.93
$0.020.18%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.28M | 3.75M | 3.08M | 3.31M | 2.65M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.28M | 3.75M | 3.08M | 3.31M | 2.65M |
| Cost of Revenue | 102.00K | 167.70K | 41.60K | 118.50K | 104.00K |
| Gross Profit | 4.18M | 3.58M | 3.04M | 3.19M | 2.55M |
| SG&A Expenses | 5.31M | 5.13M | 4.30M | 4.38M | 3.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.42M | 5.31M | 4.38M | 4.50M | 3.94M |
| Operating Income | -1.14M | -1.56M | -1.30M | -1.19M | -1.29M |
| Income Before Tax | -1.16M | -1.57M | -1.31M | -1.19M | -1.31M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.16M | -1.57M | -1.31M | -1.19M | -1.31M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.16M | -1.57M | -1.31M | -1.19M | -1.31M |
| EBIT | -1.14M | -1.56M | -1.30M | -1.19M | -1.29M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.45 | -0.62 | -0.51 | -0.34 | -0.94 |
| Normalized Basic EPS | -0.28 | -0.38 | -0.32 | -0.21 | -0.59 |
| EPS Diluted | -0.45 | -0.62 | -0.51 | -0.34 | -0.94 |
| Normalized Diluted EPS | -0.28 | -0.38 | -0.32 | -0.21 | -0.59 |
| Average Basic Shares Outstanding | 2.56M | 2.55M | 2.55M | 3.48M | 1.40M |
| Average Diluted Shares Outstanding | 2.56M | 2.55M | 2.55M | 3.48M | 1.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |